Skip to main content

Table 2 Primary and Secondary outcomes: Peak and trough anti-xa levels achieved with each enoxaparin dose

From: Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment

Outcomesa

Enoxaparin 20 mg

SC daily (n = 16)

Enoxaparin 30 mg

SC daily (n = 11)

P-value

Peak anti-xa level (IU/mL)

0.14 ± 0.09

(0.08–0.19)

0.26 ± 0.11

(0.18–0.34)

0.004

Trough anti-xa level (IU/mL)

0.03 ± 0.04

(0.01–0.05)

0.06 ± 0.03

(0.04–0.08)

0.044

  1. Abbreviations: SC Subcutaneous
  2. a Data are mean ± SD (95%CI) values unless otherwise indicated
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us